The stock has a 36-month beta value of 1.98. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for ACET is 66.10M, and at present, short sellers hold a 4.62% of that float. On February 05, 2025, the average trading volume of ACET was 581.57K shares.
ACET) stock’s latest price update
Adicet Bio Inc (NASDAQ: ACET)’s stock price has plunge by 0.76relation to previous closing price of 0.92. Nevertheless, the company has seen a 2.76% surge in its stock price over the last five trading sessions. businesswire.com reported 2025-02-05 that REDWOOD CITY, Calif. & BOSTON–(BUSINESS WIRE)–Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potential treatment of adult patients with refractory systemic lupus erythematosus (SLE) with extrarenal involvement. Fast Track Designation is a process designed.
ACET’s Market Performance
Adicet Bio Inc (ACET) has seen a 2.76% rise in stock performance for the week, with a -6.63% decline in the past month and a -25.85% plunge in the past quarter. The volatility ratio for the week is 5.60%, and the volatility levels for the past 30 days are at 7.14% for ACET. The simple moving average for the past 20 days is 1.03% for ACET’s stock, with a -28.88% simple moving average for the past 200 days.
Analysts’ Opinion of ACET
Many brokerage firms have already submitted their reports for ACET stocks, with Guggenheim repeating the rating for ACET by listing it as a “Buy.” The predicted price for ACET in the upcoming period, according to Guggenheim is $7 based on the research report published on September 30, 2024 of the previous year 2024.
ACET Trading at -3.08% from the 50-Day Moving Average
After a stumble in the market that brought ACET to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.40% of loss for the given period.
Volatility was left at 7.14%, however, over the last 30 days, the volatility rate increased by 5.60%, as shares sank -14.68% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.84% lower at present.
During the last 5 trading sessions, ACET rose by +3.10%, which changed the moving average for the period of 200-days by -54.07% in comparison to the 20-day moving average, which settled at $0.9176. In addition, Adicet Bio Inc saw -3.65% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACET starting from Kauffman Michael, who sale 5,900 shares at the price of $1.43 back on Jun 05 ’24. After this action, Kauffman Michael now owns 5,900 shares of Adicet Bio Inc, valued at $8,437 using the latest closing price.
Stock Fundamentals for ACET
Current profitability levels for the company are sitting at:
- -9.96 for the present operating margin
- 0.62 for the gross margin
The net margin for Adicet Bio Inc stands at -9.14. The total capital return value is set at -0.57. Equity return is now at value -58.04, with -49.20 for asset returns.
Based on Adicet Bio Inc (ACET), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -5.04. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is -42813.0.
Currently, EBITDA for the company is -136.53 million with net debt to EBITDA at 0.78. When we switch over and look at the enterprise to sales, we see a ratio of -0.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.64.
Conclusion
To sum up, Adicet Bio Inc (ACET) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
